Research ArticleExperimental Studies
Open Access

Comparison of Cell-death Kinetics of Recombinant Methioninase (rMETase)-treated Cancer and Normal Cells: Only Cancer Cells Undergo Methionine-depletion Catastrophe at Low rMETase Concentrations

BYUNG MO KANG, QINGHONG HAN, KOHEI MIZUTA, SEI MORINAGA, MICHAEL BOUVET and ROBERT M. HOFFMAN
Anticancer Research January 2025, 45 (1) 105-111; DOI: https://doi.org/10.21873/anticanres.17397

Abstract

Background/Aim: Methionine addiction, known as the Hoffman effect, makes cancer cells more sensitive to methionine restriction than normal cells. However, the long-term effects of methionine restriction on cancer and normal cells have not been thoroughly studied. Materials and Methods: HCT-116 human colorectal-cancer cells and Hs27 normal skin fibroblasts were treated with 0-8 U/ml of recombinant methioninase (rMETase) for 12 days. The cells were cultured in Dulbecco’s modified Eagle’s medium in 96-well tissue-culture plates. Results: HCT-116 cells were sensitive to all concentrations of rMETase from 0.125 U/ml to 8 U/ml. After day-8 of treatment, HCT-116 cells were acutely sensitive to rMETase, especially at rMETase concentrations of 0.5 U/ml or higher. Normal Hs27 fibroblasts were much less sensitive to rMETase: In the range of 0.125 U/ml to 0.5 U/ml, rMETase had no effect on Hs27 cells. rMETase concentrations up to 2 U/ml had a slight initial effect on Hs27 cells, whereas at concentrations ranging from 4 U/ml to 8 U/ml, rMETase reduced Hs27 viability over the 12-day test period, with acute loss of viability observed after eight days of exposure. Conclusion: Cancer cells were significantly more sensitive to rMETase than normal cells, with an acute loss of cell viability observed in cancer cells after eight days of treatment at concentrations of 0.5 U/ml or higher. These findings highlight the large difference in sensitivity between cancer and normal cells to rMETase and introduce the phenomenon of acute cell death in methionine restriction, which we term “methionine-depletion catastrophe”.

Key Words:

Methionine addiction is a general and fundamental hallmark of cancer, termed the Hoffman effect (1). Sugimura et al. (2) discovered in 1959 that removing methionine from the diet slowed rat-cancer growth more than removing other amino acids from the rat diet. Chello and Bertino (3) found leukemic cells arrested at low concentrations of methionine in vitro in 1973. Hoffman found that cancer cells are addicted to methionine in 1976 (4). Wang et al. (5) showed in 2019 that tumor-initiating cells are highly addicted to methionine. Methionine addiction is due to overuse of methionine by cancer cells for transmethylation reactions (6-8). Methylation reactions in cancer cells are elevated (5, 9, 10). Cancer cells arrest in late-S/G2 phase of the cell cycle when deprived of methionine (11, 12) making them more sensitive to chemotherapy (13, 14). However, the susceptibility of cancer and normal cells to recombinant methioninase (rMETase) has not been compared over a long period and over a wide range of concentrations, which the present study does.

Materials and Methods

Cell culture and preparation. The HCT-116 human colorectal-cancer cell line and Hs27 human normal fibroblasts were obtained from The American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO, Grand Island, NY, USA) with 10% fetal bovine serum (GIBCO) and 1 IU/ml Streptomycin Sulfate/Penicillin G Sodium (GIBCO) under a humidified atmosphere of 5% CO2 at 37°C. Both HCT-116 and Hs27 cells were cultured in 100 μl media in 96 well plates.

Recombinant methioninase treatment. Recombinant L-methionine α-deamino-γ-mercaptomethane-lyase (rMETase), a methionine-cleaving enzyme, originally from Pseudomonas putida, was produced in recombinant Escherichia coli by fermentation at AntiCancer Inc. (15, 16). When HCT-116 or Hs27 cells in each well reached confluence, they were treated with rMETase at 0 (control), 0.125, 0.25, 0.5, 1, 2, 4, and 8 U/ml.

Cell viability. Cell viability was measured on days 2, 4, 6, 8, 10, and 12 after rMETase treatment. To measure cell viability, 10 μl WST-8 reagent from a Cell Counting Kit-8 (Dojindo Laboratory, Kumamoto, Japan) were added to the medium in each well and the resulting optical density was measured at 450 nm using a spectrophotometer (Sunrise™, Tecan Inc. Mannedorf, Switzerland). Cell survival at each rMETase concentration was calculated as the relative survival rate compared to the untreated control group. There were n=6 wells for each rMETase concentration at each time point.

Statistical analysis. Statistical analysis was performed using IBM SPSS Statistics Version 20 (SPSS, Chicago, IL, USA). Continuous values were analyzed using the Mann-Whitney test and p-values ≤ 0.05 were considered to be statistically significant.

Results

Figure 1 shows the survival rates of HCT-116 and Hs27 cells upon treatment for up to 12 days with rMETase at concentrations ranging from 0 to 8 U/ml. The viability of HCT-116 human colorectal-cancer cells decreased over time following treatment with 0.125 U/ml to 8 U/ml of rMETase, and lower survival rates were observed at higher concentrations of rMETase. These results confirmed that HCT116 cells are highly sensitive to rMETase. From day 8 and after of rMETase treatment, the viability of HCT-116 cells sharply declined at rMETase concentrations equal or higher than 0.5 U/ml. In contrast, normal Hs27 cells were more resistant to rMETase than HCT116 cells. At rMETase concentrations equal or lower than 0.5 U/ml, there was no effect on Hs27 cell viability. At 1 and 2 U/ml rMETase concentrations, the viability of Hs27 cells initially decreased but recovered over time. However, at concentrations of 4 U/ml and 8 U/ml, the viability continued to decrease at a high rate over time, with a pattern similar to that observed in HCT-116 cells, termed methionine-depletion catastrophe..

Figure 1.
Figure 1.

Survival rates of (A) Hs27 normal fibroblasts and (B) HCT-116 colon-cancer cells treated with increasing concentrations of rMETase. Please see Materials and Methods for details.

Individual time-course analysis at each concentration of rMETase with HCT116 cells showed a significant decrease in survival over time as the rMETase concentration increased from 0.125 U/ml to 2 U/ml. In contrast, Hs27 cells exhibited relatively stable survival rates at rMETase concentrations from 0.125 U/ml to 2 U/ml. In this range of rMETase concentrations, the survival rates of HCT-116 were significantly lower than those of Hs27 cells. At the rMETase concentrations of 4 U/ml and 8 U/ml, both HCT-116 and Hs27 cells showed methionine-depletion catastrophe with an increased decline in survival over time (Figure 2).

Figure 2.
Figure 2.

Cell survival time course according to each rMETase concentration. Red line= HT-116 colon-cancer cells; blue line: Hs27 normal human fibroblasts. *: p<0.05. Please see Materials and Methods for details.

Dose-response analysis of rMETase treatment at each day showed that the difference in survival rates between cancer and normal cells increased over time at low to medium concentrations of rMETase (from 0.125 U/ml to 2 U/ml). At these rMETase concentrations, cancer cells reached methionine-depletion catastrophe, whereas the effect on normal cells was minimal. However, at higher concentrations of rMETase (4 U/ml and 8 U/ml), there was no large difference in survival rates of the cancer and normal cells, both undergoing methionine-depletion catastrophe (Figure 3).

Figure 3.
Figure 3.

Cell survival rates according to rMETase concentration at each day. Red solid line represents HCT-116 cells and blue solid line represents Hs27 fibroblasts. *: p<0.05. Please see Materials and Methods for details.

Discussion

Methionine addiction is the fundamental and general hallmark of cancer (4-13, 16-34). Although much has been discovered in over a half-century since methionine addiction was discovered, more needs to be learned about the altered transmethylation reactions in methionine-addicted cancer cells, including altered methylation of histone lysine marks in cancer cells (5, 9, 10, 21, 22). The present study showed that cancer cells rapidly undergo loss of cell viability at day-8 when treated with methioninase concentrations equal or greater than 0.5 U/ml, termed methionine-depletion catastrophe. The acute loss of cell viability does not occur in normal cells at these rMETase concentrations.

The present study demonstrating acute loss of HCT-116 cancer-cell viability after day-8 of rMETase treatment, at concentrations equal or greater than 0.5 U/ml, is consistent with the 1980 observation of Hoffman and Jacobsen (11). These results (11) demonstrated that SV-40-transformed cell lines were arrested at the late-S/G2 phase of the cell cycle at day-8 when cultured in homocysteine-containing, methionine-depleted medium. In methionine-depleted, homocysteine-containing medium, no cells were observed at day-8 in the G1 phase of the cell cycle whereas almost all the cells were in late-S/G2 phase by day-8. Thus, the G1 peak completely disappeared, leaving only the late-S/G2 peak on day-8. These results are consistent with the present results of acute decline in cancer-cell viability from day-8 even at low concentrations of rMETase.

At the high rMETase concentrations of 4 U/ml and 8 U/ml, viability of both cancer and normal cells continued to decrease over time, both undergoing methionine-depletion catastrophe. This suggests that severe or complete methionine depletion is detrimental to the survival of not only cancer cells but also of normal cells, but at only high rMETase concentrations. Therefore, it is essential to determine a safe and appropriate rMETase concentration that selectively induces cancer-cell death without affecting the survival of normal cells, as shown in the present in vitro study.

Conclusion

HCT-116 cancer cells were significantly more sensitive to rMETase than Hs27 normal fibroblasts. After 8 days of rMETase treatment at concentrations ranging from 0.5 U/ml to 8 U/ml, cancer cells experienced a pronounced decline in cell viability, termed methionine-depletion catastrophe, which occurred in the normal cells only at 4 U/ml and 8 U/ml. These findings highlight the substantial difference in rMETase sensitivity between cancer and normal cells and introduce a new phenomenon of acute viability loss in cancer cells after 8 days of treatment with rMETase at concentrations of 0.5 U/ml or higher, termed methionine-depletion catastrophe, that occurs in normal cells only at 4 and 8 units of rMETase/ml.

Future experiments will study the molecular changes occurring in cancer cells during the acute phase of methionine depletion which will help to better understand methionine addiction of cancer cells and its exploitation for cancer treatment (1, 4-13, 16-33).

Orally-administered rMETase (o-rMETase) is highly effective in patient-derived orthotopic xenograft (PDOX) mouse models and synergistic with chemotherapy (34-46). o-rMETase is beginning to show clinical promise in individual case studies (14, 47-55).

Acknowledgements

This paper is dedicated to the memory of A.R. Moossa, MD, Sun Lee, MD, Professor Gordon H. Sato, Professor Li Jiaxi, Masaki Kitajima, MD, Shigeo Yagi, PhD, Jack Geller, MD, Joseph R Bertino, MD, J.A.R. Mead, PhD, Eugene P. Frenkel, MD, John Medelsohn, MD, Professor Lev Bergelson, Professor Sheldon Penman, Professor John R. Raper and Joseph Leighton, MD. The Robert M. Hoffman Foundation for Cancer Research provided funds for the present study.

Footnotes

  • Authors’ Contributions

    BMK, RMH, and QH designed the study. QH produced rMETase. BMK conducted all experiments. BMK wrote the article and RMH revised the article. KM, SM, and MB critically read the manuscript.

  • Conflicts of Interest

    All Authors have no conflicts of interest or financial ties to disclose related to this study.

  • Received November 18, 2024.
  • Revision received December 7, 2024.
  • Accepted December 10, 2024.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Abo Qoura L,
    2. Balakin KV,
    3. Hoffman RM,
    4. Pokrovsky VS
    : The potential of methioninase for cancer treatment. Biochim Biophys Acta Rev Cancer 1879(4): 189122, 2024. DOI: 10.1016/j.bbcan.2024.189122
    OpenUrlCrossRef
  2. ↵
    1. Sugimura T,
    2. Birnbaum SM,
    3. Winitz M,
    4. Greenstein JP
    : Quantitative nutritional studies with water-soluble, chemically defined diets. VIII. The forced feeding of diets each lacking in one essential amino acid. Arch Biochem Biophys 81(2): 448-455, 1959. DOI: 10.1016/0003-9861(59)90225-5
    OpenUrlCrossRefPubMed
  3. ↵
    1. Chello PL,
    2. Bertino JR
    : Dependence of 5-methyltetrahydrofolate utilization by L5178Y murine leukemia cells in vitro on the presence of hydroxycobalamin and transcobalamin II. Cancer Res 33(8): 1898-1904, 1973.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Hoffman RM,
    2. Erbe RW
    : High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci USA 73(5): 1523-1527, 1976. DOI: 10.1073/pnas.73.5.1523
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Wang Z,
    2. Yip LY,
    3. Lee JHJ,
    4. Wu Z,
    5. Chew HY,
    6. Chong PKW,
    7. Teo CC,
    8. Ang HY,
    9. Peh KLE,
    10. Yuan J,
    11. Ma S,
    12. Choo LSK,
    13. Basri N,
    14. Jiang X,
    15. Yu Q,
    16. Hillmer AM,
    17. Lim WT,
    18. Lim TKH,
    19. Takano A,
    20. Tan EH,
    21. Tan DSW,
    22. Ho YS,
    23. Lim B,
    24. Tam WL
    : Methionine is a metabolic dependency of tumor-initiating cells. Nat Med 25(5): 825-837, 2019. DOI: 10.1038/s41591-019-0423-5
    OpenUrlCrossRefPubMed
  6. ↵
    1. Stern PH,
    2. Hoffman RM
    : Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 20(8): 663-670, 1984. DOI: 10.1007/bf02619617
    OpenUrlCrossRefPubMed
    1. Judde JG,
    2. Ellis M,
    3. Frost P
    : Biochemical analysis of the role of transmethylation in the methionine dependence of tumor cells. Cancer Res 49(17): 4859-4865, 1989.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Tisdale MJ
    : Changes in tRNA methyltransferase activity and cellular S-adenosylmethionine content following methionine deprivation. Biochim Biophys Acta 609(2): 296-305, 1980. DOI: 10.1016/0005-2787(80)90241-5
    OpenUrlCrossRefPubMed
  9. ↵
    1. Yamamoto J,
    2. Han Q,
    3. Inubushi S,
    4. Sugisawa N,
    5. Hamada K,
    6. Nishino H,
    7. Miyake K,
    8. Kumamoto T,
    9. Matsuyama R,
    10. Bouvet M,
    11. Endo I,
    12. Hoffman RM
    : Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells. Biochem Biophys Res Commun 533(4): 1034-1038, 2020. DOI: 10.1016/j.bbrc.2020.09.108
    OpenUrlCrossRefPubMed
  10. ↵
    1. Aoki Y,
    2. Yamamoto J,
    3. Tome Y,
    4. Hamada K,
    5. Masaki N,
    6. Inubushi S,
    7. Tashiro Y,
    8. Bouvet M,
    9. Endo I,
    10. Nishida K,
    11. Hoffman RM
    : Over-methylation of Histone H3 Lysines is a common molecular change among the three major types of soft-tissue sarcoma in patient-derived xenograft (PDX) mouse models. Cancer Genomics Proteomics 18(6): 715-721, 2021. DOI: 10.21873/cgp.20292
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Hoffman RM,
    2. Jacobsen SJ
    : Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc Natl Acad Sci U S A 77(12): 7306-7310, 1980. DOI: 10.1073/pnas.77.12.7306
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Yano S,
    2. Li S,
    3. Han Q,
    4. Tan Y,
    5. Bouvet M,
    6. Fujiwara T,
    7. Hoffman RM
    : Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity. Oncotarget 5(18): 8729-8736, 2014. DOI: 10.18632/oncotarget.2369
    OpenUrlCrossRefPubMed
  13. ↵
    1. Stern PH,
    2. Hoffman RM
    : Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76(4): 629-639, 1986. DOI: 10.1093/jnci/76.4.629
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kubota Y,
    2. Han Q,
    3. Morinaga S,
    4. Tsunoda T,
    5. Hoffman RM
    : Rapid reduction of CEA and stable metastasis in an NRAS-mutant rectal-cancer patient treated with FOLFIRI and bevacizumab combined with oral recombinant methioninase and a low-methionine diet upon metastatic recurrence after FOLFIRI and bevacizumab treatment alone. In Vivo 37(5): 2134-2138, 2023. DOI: 10.21873/invivo.13310
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Tan Y,
    2. Xu M,
    3. Tan X,
    4. Tan X,
    5. Wang X,
    6. Saikawa Y,
    7. Nagahama T,
    8. Sun X,
    9. Lenz M,
    10. Hoffman RM
    : Overexpression and large-scale production of recombinantl-methionine-α-deamino-γ-mercapto methane-lyase for novel anticancer therapy. Protein Expr Purif 9(2): 233-245, 1997. DOI: 10.1006/prep.1996.0700
    OpenUrlCrossRefPubMed
  16. ↵
    1. Hoffman RM
    : Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther 15(1): 21-31, 2015. DOI: 10.1517/14712598.2015.963050
    OpenUrlCrossRefPubMed
    1. Coalson DW,
    2. Mecham JO,
    3. Stern PH,
    4. Hoffman RM
    : Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells. Proc Natl Acad Sci USA 79(14): 4248-4251, 1982. DOI: 10.1073/pnas.79.14.4248
    OpenUrlAbstract/FREE Full Text
    1. Stern PH,
    2. Wallace CD,
    3. Hoffman RM
    : Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 119(1): 29-34, 1984. DOI: 10.1002/jcp.1041190106
    OpenUrlCrossRefPubMed
    1. Hoffman RM
    : Altered methionine metabolism and transmethylation in cancer. Anticancer Res 5(1): 1-30, 1985.
    OpenUrlPubMed
    1. Stern PH,
    2. Mecham JO,
    3. Wallace CD,
    4. Hoffman RM
    : Reduced free-methionine in methionine-dependent SV40-transformed human fibroblasts synthesizing apparently normal amounts of methionine. J Cell Physiol 117(1): 9-14, 1983. DOI: 10.1002/jcp.1041170103
    OpenUrlCrossRefPubMed
  21. ↵
    1. Aoki Y,
    2. Han Q,
    3. Tome Y,
    4. Yamamoto J,
    5. Kubota Y,
    6. Masaki N,
    7. Obara K,
    8. Hamada K,
    9. Wang JD,
    10. Inubushi S,
    11. Bouvet M,
    12. Clarke SG,
    13. Nishida K,
    14. Hoffman RM
    : Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylation. Front Oncol 12: 1009548, 2022. DOI: 10.3389/fonc.2022.1009548
    OpenUrlCrossRefPubMed
  22. ↵
    1. Yamamoto J,
    2. Inubushi S,
    3. Han Q,
    4. Tashiro Y,
    5. Sugisawa N,
    6. Hamada K,
    7. Aoki Y,
    8. Miyake K,
    9. Matsuyama R,
    10. Bouvet M,
    11. Clarke SG,
    12. Endo I,
    13. Hoffman RM
    : Linkage of methionine addiction, histone lysine hypermethylation, and malignancy. iScience 25(4): 104162, 2022. DOI: 10.1016/j.isci.2022.104162
    OpenUrlCrossRefPubMed
    1. Aoki Y,
    2. Tome Y,
    3. Han Q,
    4. Yamamoto J,
    5. Hamada K,
    6. Masaki N,
    7. Kubota Y,
    8. Bouvet M,
    9. Nishida K,
    10. Hoffman RM
    : Deletion of MTAP highly sensitizes osteosarcoma cells to methionine restriction with recombinant methioninase. Cancer Genomics Proteomics 19(3): 299-304, 2022. DOI: 10.21873/cgp.20321
    OpenUrlAbstract/FREE Full Text
    1. Aoki Y,
    2. Tome Y,
    3. Han Q,
    4. Yamamoto J,
    5. Hamada K,
    6. Masaki N,
    7. Bouvet M,
    8. Nishida K,
    9. Hoffman RM
    : Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation. Biochem Biophys Rep 28:101177, 2021. DOI: 10.1016/j.bbrep.2021.101177
    OpenUrlCrossRefPubMed
    1. Hoffman RM,
    2. Jacobsen SJ,
    3. Erbe RW
    : Reversion to methionine independence in simian virus 40-transformed human and malignant rat fibroblasts is associated with altered ploidy and altered properties of transformation. Proc Natl Acad Sci 76(3): 1313-1317, 1979. DOI: 10.1073/pnas.76.3.1313
    OpenUrlAbstract/FREE Full Text
    1. Hoffman RM,
    2. Jacobsen SJ,
    3. Erbe RW
    : Reversion to methionine independence by malignant rat and SV40-transformed human fibroblasts. Biochem Biophys Res Commun 82(1): 228-234, 1978. DOI: 10.1016/0006-291x(78)90600-9
    OpenUrlCrossRefPubMed
    1. Yamamoto J,
    2. Aoki Y,
    3. Han Q,
    4. Sugisawa N,
    5. Sun YU,
    6. Hamada K,
    7. Nishino H,
    8. Inubushi S,
    9. Miyake K,
    10. Matsuyama R,
    11. Bouvet M,
    12. Endo I,
    13. Hoffman RM
    : Reversion from methionine addiction to methionine independence results in loss of tumorigenic potential of highly-malignant lung-cancer cells. Anticancer Res 41(2): 641-643, 2021. DOI: 10.21873/anticanres.14815
    OpenUrlAbstract/FREE Full Text
    1. Hoffman RM
    : Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta 738: 49-87, 1984. DOI: 10.1016/0304-419x(84)90019-2
    OpenUrlCrossRefPubMed
    1. Ghergurovich JM,
    2. Xu X,
    3. Wang JZ,
    4. Yang L,
    5. Ryseck RP,
    6. Wang L,
    7. Rabinowitz JD
    : Methionine synthase supports tumour tetrahydrofolate pools. Nat Metab 3(11): 1512-1520, 2021. DOI: 10.1038/s42255-021-00465-w
    OpenUrlCrossRefPubMed
    1. Sullivan MR,
    2. Darnell AM,
    3. Reilly MF,
    4. Kunchok T,
    5. Joesch-Cohen L,
    6. Rosenberg D,
    7. Ali A,
    8. Rees MG,
    9. Roth JA,
    10. Lewis CA,
    11. Vander Heiden MG
    : Methionine synthase is essential for cancer cell proliferation in physiological folate environments. Nat Metab 3(11): 1500-1511, 2021. DOI: 10.1038/s42255-021-00486-5
    OpenUrlCrossRef
    1. Mecham JO,
    2. Rowitch D,
    3. Wallace CD,
    4. Stern PH,
    5. Hoffman RM
    : The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 117(2): 429-34, 1983. DOI: 10.1016/0006-291x(83)91218-4
    OpenUrlCrossRefPubMed
    1. Tan Y,
    2. Xu M,
    3. Hoffman RM
    : Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells In Vitro. Anticancer Res 30(4): 1041-6, 2010
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Jacobsen SJ,
    2. Hoffman RM,
    3. Erbe RW
    : Regulation of methionine adenosyltransferase in normal diploid and simian virus 40-transformed human fibroblasts. J Natl Cancer Inst 65(6): 1237-44, 1980
    OpenUrlPubMed
  34. ↵
    1. Kubota Y,
    2. Han Q,
    3. Aoki Y,
    4. Masaki N,
    5. Obara K,
    6. Hamada K,
    7. Hozumi C,
    8. Wong ACW,
    9. Bouvet M,
    10. Tsunoda T,
    11. Hoffman RM
    : Synergy of combining methionine restriction and chemotherapy: the disruptive next generation of cancer treatment. Cancer Diagn Progn 3(3): 272-281, 2023. DOI: 10.21873/cdp.10212
    OpenUrlCrossRefPubMed
    1. Higuchi T,
    2. Sugisawa N,
    3. Yamamoto J,
    4. Oshiro H,
    5. Han Q,
    6. Yamamoto N,
    7. Hayashi K,
    8. Kimura H,
    9. Miwa S,
    10. Igarashi K,
    11. Tan Y,
    12. Kuchipudi S,
    13. Bouvet M,
    14. Singh SR,
    15. Tsuchiya H,
    16. Hoffman RM
    : The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. Cancer Chemother Pharmacol 85(2): 285-291, 2020. DOI: 10.1007/s00280-019-03986-0
    OpenUrlCrossRefPubMed
    1. Masaki N,
    2. Han Q,
    3. Wu NF,
    4. Samonte C,
    5. Wu J,
    6. Hozumi C,
    7. Obara K,
    8. Kubota Y,
    9. Aoki Y,
    10. Miyazaki J,
    11. Hoffman RM
    : Oral-recombinant methioninase lowers the effective dose and eliminates toxicity of cisplatinum for primary osteosarcoma of the mammary gland in a patient-derived orthotopic xenograft mouse model. In Vivo 36(6): 2598-2603, 2022. DOI: 10.21873/invivo.12994
    OpenUrlAbstract/FREE Full Text
    1. Masaki N,
    2. Han Q,
    3. Samonte C,
    4. Wu NF,
    5. Hozumi C,
    6. Wu J,
    7. Obara K,
    8. Kubota Y,
    9. Aoki Y,
    10. Bouvet M,
    11. Hoffman RM
    : Oral-recombinant methioninase in combination with rapamycin eradicates osteosarcoma of the breast in a patient-derived orthotopic xenograft mouse model. Anticancer Res 42(11): 5217-5222, 2022. DOI: 10.21873/anticanres.16028
    OpenUrlAbstract/FREE Full Text
    1. Aoki Y,
    2. Tome Y,
    3. Wu NF,
    4. Yamamoto J,
    5. Hamada K,
    6. Han Q,
    7. Bouvet M,
    8. Nishida K,
    9. Hoffman RM
    : Oral-recombinant methioninase converts an osteosarcoma from docetaxel-resistant to -sensitive in a clinically-relevant patient-derived orthotopic-xenograft (PDOX) mouse model. Anticancer Res 41(4): 1745-1751, 2021. DOI: 10.21873/anticanres.14939
    OpenUrlAbstract/FREE Full Text
    1. Higuchi T,
    2. Han Q,
    3. Miyake K,
    4. Oshiro H,
    5. Sugisawa N,
    6. Tan Y,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Bouvet M,
    13. Singh SR,
    14. Tsuchiya H,
    15. Hoffman RM
    : Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun 523(1): 135-139, 2020. DOI: 10.1016/j.bbrc.2019.12.024
    OpenUrlCrossRefPubMed
    1. Miyake M,
    2. Miyake K,
    3. Han Q,
    4. Igarashi K,
    5. Kawaguchi K,
    6. Barangi M,
    7. Kiyuna T,
    8. Sugisawa N,
    9. Higuchi T,
    10. Oshiro H,
    11. Zhang Z,
    12. Razmjooei S,
    13. Bouvet M,
    14. Endo I,
    15. Hoffman RM
    : Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer. Biochem Biophys Res Commun 643: 48-54, 2023. DOI: 10.1016/j.bbrc.2022.12.062
    OpenUrlCrossRefPubMed
    1. Higuchi T,
    2. Oshiro H,
    3. Miyake K,
    4. Sugisawa N,
    5. Han Q,
    6. Tan Y,
    7. Park J,
    8. Zhang Z,
    9. Razmjooei S,
    10. Yamamoto N,
    11. Hayashi K,
    12. Kimura H,
    13. Miwa S,
    14. Igarashi K,
    15. Bouvet M,
    16. Chawla SP,
    17. Singh SR,
    18. Tsuchiya H,
    19. Hoffman RM
    : Oral recombinant methioninase, combined with oral caffeine and injected cisplatinum, overcome cisplatinum-resistance and regresses patient-derived orthotopic xenograft model of osteosarcoma. Anticancer Res 39(9): 4653-4657, 2019. DOI: 10.21873/anticanres.13646
    OpenUrlAbstract/FREE Full Text
    1. Sugisawa N,
    2. Higuchi T,
    3. Han Q,
    4. Hozumi C,
    5. Yamamoto J,
    6. Tashiro Y,
    7. Nishino H,
    8. Kawaguchi K,
    9. Bouvet M,
    10. Murata T,
    11. Unno M,
    12. Hoffman RM
    : Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Cancer Chemother Pharmacol 88(1): 61-67, 2021. DOI: 10.1007/s00280-021-04261-x
    OpenUrlCrossRefPubMed
    1. Kawaguchi K,
    2. Miyake K,
    3. Han Q,
    4. Li S,
    5. Tan Y,
    6. Igarashi K,
    7. Kiyuna T,
    8. Miyake M,
    9. Higuchi T,
    10. Oshiro H,
    11. Zhang Z,
    12. Razmjooei S,
    13. Wangsiricharoen S,
    14. Bouvet M,
    15. Singh SR,
    16. Unno M,
    17. Hoffman RM
    : Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. Cancer Lett 432: 251-259, 2018. DOI: 10.1016/j.canlet.2018.06.016
    OpenUrlCrossRefPubMed
    1. Oshiro H,
    2. Tome Y,
    3. Kiyuna T,
    4. Yoon SN,
    5. Lwin TM,
    6. Han Q,
    7. Tan Y,
    8. Miyake K,
    9. Higuchi T,
    10. Sugisawa N,
    11. Katsuya Y,
    12. Park JH,
    13. Zang Z,
    14. Razmjooei S,
    15. Bouvet M,
    16. Clary B,
    17. Singh SR,
    18. Kanaya F,
    19. Nishida K,
    20. Hoffman RM
    : Oral recombinant methioninase overcomes colorectal-cancer liver metastasis resistance to the combination of 5-fluorouracil and oxaliplatinum in a patient-derived orthotopic xenograft mouse model. Anticancer Res 39(9): 4667-4671, 2019. DOI: 10.21873/anticanres.13648
    OpenUrlAbstract/FREE Full Text
    1. Higuchi T,
    2. Kawaguchi K,
    3. Miyake K,
    4. Han Q,
    5. Tan Y,
    6. Oshiro H,
    7. Sugisawa N,
    8. Zhang Z,
    9. Razmjooei S,
    10. Yamamoto N,
    11. Hayashi K,
    12. Kimura H,
    13. Miwa S,
    14. Igarashi K,
    15. Chawla SP,
    16. Singh AS,
    17. Eilber FC,
    18. Singh SR,
    19. Tsuchiya H,
    20. Hoffman RM
    : Oral recombinant methioninase combined with caffeine and doxorubicin induced regression of a doxorubicin-resistant synovial sarcoma in a PDOX mouse model. Anticancer Res 38(10): 5639-5644, 2018. DOI: 10.21873/anticanres.12899
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Kim MJ,
    2. Han Q,
    3. Bouvet M,
    4. Hoffman RM,
    5. Park JH
    : Recombinant oral methioninase (o-rMETase) combined with oxaliplatinum plus 5-fluorouracil improves survival of mice with massive colon-cancer peritoneal carcinomatosis. Anticancer Res 43(1): 19-24, 2023. DOI: 10.21873/anticanres.16129
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Han Q,
    2. Tan Y,
    3. Hoffman RM
    : Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methionine in a high-stage ovarian cancer patient. Anticancer Res 40(5): 2813-2819, 2020. DOI: 10.21873/anticanres.14254
    OpenUrlAbstract/FREE Full Text
    1. Kubota Y,
    2. Han Q,
    3. Hozumi C,
    4. Masaki N,
    5. Yamamoto J,
    6. Aoki Y,
    7. Tsunoda T,
    8. Hoffman RM
    : Stage IV pancreatic cancer patient treated with FOLFIRINOX combined with oral methioninase: a highly-rare case with long-term stable disease. Anticancer Res 42(5): 2567-2572, 2022. DOI: 10.21873/anticanres.15734
    OpenUrlAbstract/FREE Full Text
    1. Kubota Y,
    2. Han Q,
    3. Masaki N,
    4. Hozumi C,
    5. Hamada K,
    6. Aoki Y,
    7. Obara K,
    8. Tsunoda T,
    9. Hoffman RM
    : Elimination of axillary-lymph-node metastases in a patient with invasive lobular breast cancer treated by first-line neo-adjuvant chemotherapy combined with methionine restriction. Anticancer Res 42(12): 5819-5823, 2022. DOI: 10.21873/anticanres.16089
    OpenUrlAbstract/FREE Full Text
    1. Kubota Y,
    2. Han Q,
    3. Hamada K,
    4. Aoki Y,
    5. Masaki N,
    6. Obara K,
    7. Tsunoda T,
    8. Hoffman RM
    : Long-term stable disease in a rectal-cancer patient treated by methionine restriction with oral recombinant methioninase and a low-methionine diet. Anticancer Res 42(8): 3857-3861, 2022. DOI: 10.21873/anticanres.15877
    OpenUrlAbstract/FREE Full Text
    1. Sato M,
    2. Han Q,
    3. Mori R,
    4. Mizuta K,
    5. Kang BM,
    6. Morinaga S,
    7. Kobayashi N,
    8. Ichikawa Y,
    9. Nakajima A,
    10. Hoffman RM
    : Reduction of tumor biomarkers from very high to normal and extensive mmetastatic lesions to undetectability in a patient with stage IV HER2-positive breast cancer treated with low-dose trastuzumab deruxtecan in combination with oral recombinant methioninase and a low-methionine diet. Anticancer Res 44(4): 1499-1504, 2024. DOI: 10.21873/anticanres.16946
    OpenUrlAbstract/FREE Full Text
    1. Sato M,
    2. Han Q,
    3. Hozumi C,
    4. Kujiraoka H,
    5. Mizuta K,
    6. Morinaga S,
    7. Kang BM,
    8. Kobayashi N,
    9. Ichikawa Y,
    10. Nakajima A,
    11. Hoffman RM
    : First-line chemotherapy in combination with oral recombinant methioninase and a low-methionine diet for a stage IV inoperable pancreatic-cancer patient resulted in 40% tumor reduction and an 86% CA19-9 biomarker decrease. Anticancer Res 44(9): 3885-3889, 2024. DOI: 10.21873/anticanres.17215
    OpenUrlAbstract/FREE Full Text
    1. Sato M,
    2. Han Q,
    3. Mizuta K,
    4. Mori R,
    5. Kang BM,
    6. Morinaga S,
    7. Kobayashi N,
    8. Ichikawa Y,
    9. Nakajima A,
    10. Hoffman RM
    : Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet. In Vivo 38(3): 1459-1464, 2024. DOI: 10.21873/invivo.13591
    OpenUrlAbstract/FREE Full Text
    1. Han Q,
    2. Hoffman RM
    : Chronic treatment of an advanced prostate-cancer patient with oral methioninase resulted in longterm stabilization of rapidly rising PSA levels. In Vivo 35(4): 2171-2176, 2021. DOI: 10.21873/invivo.12488
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Han Q,
    2. Hoffman RM
    : Lowering and stabilizing PSA levels in advanced-prostate cancer patients with oral methioninase. Anticancer Res 41(4): 1921-1926, 2021. DOI: 10.21873/anticanres.14958
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Comparison of Cell-death Kinetics of Recombinant Methioninase (rMETase)-treated Cancer and Normal Cells: Only Cancer Cells Undergo Methionine-depletion Catastrophe at Low rMETase Concentrations
BYUNG MO KANG, QINGHONG HAN, KOHEI MIZUTA, SEI MORINAGA, MICHAEL BOUVET, ROBERT M. HOFFMAN
Anticancer Research Jan 2025, 45 (1) 105-111; DOI: 10.21873/anticanres.17397
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords